Neoadjuvant immunotherapy is also being tested in ERBB2-negative early breast cancer in combination with olaparib (I-SPY), in ERBB-2-positive breast cancer (neoPATH, IMPASSION 051) and hormone-receptor-positive breast cancer (GIADA trial). Here, ERBB2 is linked to breast carcinoma.